Blood Protein Panel Predicts Crohn's Disease Years Early
A 29-protein signature in blood samples identified individuals who later developed Crohn's disease, in some cases up to 16 years before diagnosis.
Updated on Nov. 9, 2026 in Diseases — General
Live Poll
Would you want a blood test that predicts bowel disease years in advance?
Researchers have identified a blood-based protein signature that distinguishes people who later develop Crohn's disease from matched controls. The signature's lead time before diagnosis extended up to 16 years.
Why it matters
Biomarkers capable of flagging individuals at elevated risk before symptoms appear could open a window for early preventive strategies. Such tools are currently lacking for inflammatory bowel disease.
The study measured 178 proteins on Olink platforms in population-based cohorts of at least 180,000 individuals, with a discovery cohort of 312 people. Accuracy ranged from an AUC of 0.85 to 1.0 across cohorts, but fell to 0.58 when compared with healthy twin siblings.
The details
Researchers compared blood samples from individuals later diagnosed with inflammatory bowel disease against age- and sex-matched controls who remained free of the disease. Machine-learning methods identified proteins associated with preclinical disease, and downregulated proteins linked to gut barrier integrity and macrophage function correlated with time to diagnosis.
Health Landscape
The findings extend proteomic biomarker research by applying Olink-based protein measurement to preclinical Crohn's disease in large population cohorts. The approach shifts focus from diagnosing established inflammatory bowel disease toward identifying at-risk individuals years in advance.
The findings suggest that people at elevated risk for Crohn's disease might eventually be identified through blood testing well before symptoms appear. Any practical use of such testing would depend on further research into whether early measures such as diet or medication can change disease progression.
The takeaway
A blood-based protein panel may one day flag people at risk for Crohn's disease long before symptoms emerge, though its clinical value remains to be tested. The findings point to gut barrier and immune-cell proteins as possible future therapeutic targets.
Further reading
Explore more in Diseases — General for context on inflammatory bowel conditions.
Source note: This article includes information reported by Derm Immuno Today.
Live Poll
Would you want a blood test that predicts bowel disease years in advance?
